ative antifungal drug approved in more than 20years and the first non-azole therapy for the treatment of vaginal yeast infections.
About Brexafemme(ibrexafungerp tablets), for oral use
Brexafemme is the trade name for ibrexafungerp, a novel oral antifungal approved for the treatment of vulvovaginal candidiasis(VVC), also known as vaginal yeast infection.
Brexafemme represents the first approved drug in a new antifungal class in over 20 years and is the first and only treatment for vaginal yeast infections which is both oral and non-azole.
Indication
Brexafemme is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis(VVC). |
